P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY

• Stephen Spurgeon,
• Matthew Mei,
• Paul M. Barr,
• Jacqueline Barrientos,
• Sven de Vos,
• Richard Furman,
• Krish Patel,
• Philip Thompson,
• Michael Y. Choi,
• Avyakta Kallam,
• Siruo Wang,
• Uzor Ogbu,
• Patricia Marinello,
• Michael Wang

Affiliations

Stephen Spurgeon

1 Oregon Health and Science University, Portland, United States

Matthew Mei

2 CIty of Hope, Duarte, United States

Paul M. Barr

3 University of Rochester, Rochester, United States

Jacqueline Barrientos

4 Mount Sinai Medical Center, Miami Beach, United States

Sven de Vos

5 UCLA Hematology Oncology, Santa Monica, United States

Richard Furman

6 Weill Cornell Medical College, New York, United States

Krish Patel

7 Swedish Medical Center, Seattle, United States

Philip Thompson

8 The University of Texas MD Anderson Cancer Center, Houston, United States

Michael Y. Choi

9 University of California San Diego, La Jolla, United States

Avyakta Kallam

10 University of Nebraska Medical Center, Omaha, United States

Siruo Wang

11 Merck & Co Inc, Rahway, United States

Uzor Ogbu

11 Merck & Co Inc, Rahway, United States

Patricia Marinello

11 Merck & Co Inc, Rahway, United States

Michael Wang

8 The University of Texas MD Anderson Cancer Center, Houston, United States